Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 09 2021
13 09 2021
Historique:
received:
15
12
2020
accepted:
17
08
2021
entrez:
14
9
2021
pubmed:
15
9
2021
medline:
16
12
2021
Statut:
epublish
Résumé
Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer's disease. Unfortunately, like Alzheimer's disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs' cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.
Identifiants
pubmed: 34518582
doi: 10.1038/s41598-021-97404-2
pii: 10.1038/s41598-021-97404-2
pmc: PMC8438013
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Butyrylcholinesterase
EC 3.1.1.8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18098Informations de copyright
© 2021. The Author(s).
Références
Curr Alzheimer Res. 2012 Mar;9(3):298-314
pubmed: 21875411
Alzheimers Res Ther. 2018 Dec 27;10(1):126
pubmed: 30591071
Vet J. 2010 Jun;184(3):277-81
pubmed: 20005753
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
Front Nutr. 2018 Dec 12;5:127
pubmed: 30619873
Brain Res. 2006 Jan 19;1069(1):216-26
pubmed: 16423332
Signal Transduct Target Ther. 2019 Aug 23;4:29
pubmed: 31637009
Acta Vet Scand. 2016 Feb 29;58:17
pubmed: 26927954
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar;29(3):489-98
pubmed: 15795058
J Alzheimers Dis. 2011;26(1):143-55
pubmed: 21593569
Gerontology. 2018;64(2):165-171
pubmed: 29065419
CNS Neurol Disord Drug Targets. 2017;16(7):820-827
pubmed: 28176640
Chem Commun (Camb). 2019 Mar 26;55(26):3765-3768
pubmed: 30864579
Vet Clin North Am Small Anim Pract. 2012 Jul;42(4):749-68, vii
pubmed: 22720812
Sci Rep. 2016 Dec 21;6:39495
pubmed: 28000737
Vet J. 2013 Oct;198(1):176-81
pubmed: 23988334
Ann Intern Med. 2020 May 19;172(10):669-677
pubmed: 32340038
J Neurosci. 2015 Jan 21;35(3):1199-210
pubmed: 25609634
EMBO Mol Med. 2018 Nov;10(11):
pubmed: 30224383
Front Aging Neurosci. 2013 Dec 30;5:99
pubmed: 24416017
Front Neurosci. 2019 Jun 12;13:604
pubmed: 31249505